Cytokinetics launches ASPEN-HCM real-world study of MYQORZO in obstructive hypertrophic cardiomyopathy

• Cytokinetics launched ASPEN-HCM, a prospective real-world study tracking MYQORZO in adults with symptomatic obstructive hypertrophic cardiomyopathy.
• No results have been presented; the study will collect outcomes over 12 to 36 months in routine clinical practice.
• Focus includes real-world safety, symptom improvement, functional status, treatment persistence, patient-reported experience, healthcare utilization, and cardiac remodeling trends.
• Program targets about 400 patients across 13 sites, aiming to support post-launch positioning versus invasive septal reduction procedures.
• MYQORZO carries a boxed warning for heart failure risk, requires echocardiogram monitoring, and is distributed through a restricted REMS program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytokinetics Incorporated published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609300730PRIMZONEFULLFEED9836636) on September 30, 2026, and is solely responsible for the information contained therein.